2025 AHA Expanded Hypertension Guideline Analysis

Executive Summary: Paradigm Shifts

The 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline represents the most comprehensive revision since the landmark 2017 update. Developed through collaboration among thirteen professional organizations, it involved systematic review of over 15,000 publications from 2015–2024.

Evaluation and Diagnosis

Blood Pressure Measurement Standards

• Class 1: Office BP with standardized protocol (empty bladder, 5-min rest, back supported, feet flat, arm at heart level)
• Class 2a: Automated oscillometric devices preferred over auscultatory methods
• Class 3 (Harm): Cuffless devices — no current technology meets accuracy standards for clinical decision-making

Out-of-Office Monitoring: Now Essential

White-Coat and Masked Hypertension

• White-coat HTN (15–30%): Class 2a recommendation for exclusion before diagnosis when office BP 130–159/80–99 mmHg
• Masked HTN (10–15%): Class 2b screening recommended. Risk factors: male sex, obesity, DM, CKD, OSA, high-normal office BP, occupational stress

Secondary Hypertension: Expanded Screening

Primary Aldosteronism

Renal Artery Stenosis

• Class 1: Medical therapy for atherosclerotic RAS (CORAL and ASTRAL trials negative for revascularization)
• Class 2a for revascularization ONLY if: Resistant HTN despite maximally tolerated therapy, recurrent flash pulmonary edema, or progressive renal insufficiency on ACEi/ARB
• FMD Exception: Fibromuscular dysplasia warrants angioplasty (often curative), distinguished from atherosclerotic disease

PREVENT Calculator and Treatment Thresholds

The PREVENT calculator replaces the Pooled Cohort Equations, deriving from 3.28 million individuals across 46 contemporary cohorts (vs. PCE from cohorts enrolled 1987–2002). The 7.5% threshold for Stage 1 HTN treatment aligns with statin therapy thresholds.

Treatment Initiation

• Stage 1 (130–139/80–89) + PREVENT ≥7.5%: Pharmacotherapy
• Stage 1 + PREVENT <7.5%: Class 1 for medication after failed 3–6 month lifestyle trial
• Stage 2 (≥140/90): Strong Class 1 for initial dual therapy (achieves target 6 months faster)

Lifestyle Interventions with Quantified BP Reductions

Pharmacotherapy and BP Goals

First-Line Agents and Combination Therapy

• Class 1 first-line: Thiazide-type diuretics (chlorthalidone preferred), long-acting DHP CCBs, ACEi, ARBs
• Class 1: Initial dual therapy for Stage 2 HTN — single-pill combinations improve adherence by 20–25%
• Class 3 (Harm): Dual RAAS blockade (ACEi + ARB or + aliskiren) — increased hyperkalemia, hypotension, AKI without CV benefit (ONTARGET, ALTITUDE)

Blood Pressure Goals

Target hierarchy — read in order. The 2025 AHA/ACC primary treatment target is <130/80 mmHg for all high-risk adults. An SBP <120 mmHg is an intensive option for selected patients who tolerate it — not the default goal — and is explicitly harmful in several acute settings (see Cerebrovascular Disease and Hypertensive Emergencies below).

• Primary target — <130/80 mmHg in all high-risk patients before considering further intensification
• Intensive option — SBP <120 mmHg when tolerated in selected patients — SPRINT (NEJM 2015;373:2103–2116, PMID 26551272): 25% RRR primary CV outcome (HR 0.75, ARR 1.6%, NNT 61), 27% RRR all-cause mortality (HR 0.73, ARR 1.2%, NNT 90). Caveat: SPRINT used unattended automated office BP (AOBP), which reads 5–10 mmHg lower than typical clinic BP — an SBP <120 SPRINT target corresponds to roughly 125–130 in conventional clinic measurement. Excluded diabetes, prior stroke, proteinuric CKD, dementia, nursing-home residents.
• Not universal — an SBP <120 mmHg target is contraindicated in several acute settings, e.g. post-thrombectomy ischemic stroke (Class 3 Harm; ENCHANTED2/MT, OPTIMAL-BP). See Cerebrovascular Disease below.
• Avoid frail elderly, orthostatic hypotension, or limited life expectancy for intensive targets

Resistant Hypertension

• Affects 10–15% of treated hypertensive patients
• Class 1: Spironolactone as fourth-line (20–25 mmHg additional SBP reduction) when eGFR ≥45
• Class 2b: Renal denervation (5–10 mmHg office SBP reduction; 30–40% non-response rate)
• Class 1: Multidisciplinary team evaluation required before invasive intervention

Comorbidity Management

Diabetes

• Class 1 (Strengthened): RAAS inhibition in diabetic patients with any albuminuria (including <30 mg/g)
• Target <130/80 mmHg. GLP-1 RAs and SGLT2i provide additive 3–5 mmHg BP reduction

CKD

• Unified <130 mmHg systolic target across all CKD stages
• KDIGO 2021 does not say the same thing — teach both. KDIGO 2021 (Blood Pressure in CKD) suggests a systolic target <120 mmHg when tolerated, using standardized office measurement (grade 2B, driven by the CKD subgroup of SPRINT). It explicitly excludes kidney transplant recipients and patients on dialysis. Much of the gap is measurement technique rather than disagreement about physiology: KDIGO's lower number presumes a standardized or unattended reading, which most routine clinic cuffs do not meet — the same AOBP caveat noted under Blood Pressure Goals above.
• RAAS inhibition mandatory for albuminuria ≥30 mg/g
• Acceptable: 30% creatinine increase with RAAS initiation (hemodynamic, not progressive nephropathy)

Cerebrovascular Disease

Hypertensive Emergencies and Severe Hypertension

True Hypertensive Emergency Targets

Hypertension and Pregnancy

• Class 1: Treatment at ≥140/90 mmHg (CHAP trial: treating mild chronic HTN reduces adverse pregnancy outcomes without fetal risks)
• Preferred agents: Methyldopa, labetalol (avoid in asthma), extended-release nifedipine
• Class 3 (Harm): Atenolol (IUGR association), ACEi, ARBs, MRAs (teratogenic)
• Severe HTN (≥160/110): Treat within 30–60 minutes — delayed treatment associated with maternal stroke
• Postpartum: Surveillance through 12 weeks for delayed preeclampsia

Orthostatic Hypotension